1. Scrip
  2. >>Business

Novo Bets On ‘Chequered’ CB1r Approach In Diabetic Kidney Disease With Inversago Buy

For Up To $1.08bn

 
• By Ayisha Sharma

The Danish firm’s Q2 sales fell short of expectations due to poor rare disease and diabetes performance, but a potentially billion-dollar buy of Inversago stole attention as observers highlighted the historical risks of targeting the cannabinoid-1 receptor.  

paper cutout of kidneys with sugar cubes on them
Diabetes Is The Leading Cause Of Kidney Disease • Source: Shutterstock
Key Takeaways:

  • Q2 sales increased by 32% in constant currencies to total DKK54.3bn ($8.03bn).

  • With the Inversago acquisition, Novo will get hold of lead diabetic kidney disease candidate, INV-202.

  • Prior attempts to block CB1r have ended in serious psychological side effects and regulatory failure but Inversago claims its next-generation compounds could circumvent these issues.

Novo Nordisk A/S has plunged into the traditionally challenging cannabinoid-1 (CB1) receptor-targeting space in metabolic diseases with an acquisition of Canadian biotech Inversago

The Danish major’s second-quarter sales increased by 32% in constant currencies to DKK54.3bn ($8.03bn) but missed company consensus of DKK55.37bn by 2%

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business